<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Biosci. Rep</journal-id><journal-id journal-id-type="hwp">ppbioscirep</journal-id><journal-id journal-id-type="publisher-id">BSR</journal-id><journal-title-group><journal-title>Bioscience Reports</journal-title></journal-title-group><issn pub-type="ppub">0144-8463</issn><issn pub-type="epub">1573-4935</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6265616</article-id><article-id pub-id-type="doi">10.1042/BSR20180694</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>42</subject><subject>21</subject><subject>39</subject></subj-group></article-categories><title-group><article-title>Association between <italic>Cyclin D1</italic> G870A (rs9344) polymorphism and cancer risk in Indian population: meta-analysis and trial sequential analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1190-7356</contrib-id><name><surname>Thakur</surname><given-names>Nisha</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="corresp" rid="COR1"/></contrib><contrib contrib-type="author"><name><surname>Kumari</surname><given-names>Suchitra</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mehrotra</surname><given-names>Ravi</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="corresp" rid="COR1"/></contrib><aff id="A1"><label>1</label>Division of Molecular Diagnostics, National Institute of Cancer Prevention and Research (NICPR)ICMR, I-7, Sector-39, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301, India</aff><aff id="A2"><label>2</label>Data Management Laboratory, National Institute of Cancer Prevention and Research (NICPR)ICMR, I-7, Sector-39, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301, India</aff><aff id="A3"><label>3</label>Division of Preventive Oncology, National Institute of Cancer Prevention and Research (NICPR)ICMR, I-7, Sector-39, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301, India</aff></contrib-group><author-notes><corresp id="COR1"><bold>Correspondence:</bold> Ravi Mehrotra (<email>rm8509@gmail.com</email>) or Nisha Thakur (<email>nisha_icpo@yahoo.co.in</email>; <email>nisha.thakur@gov.in</email>)</corresp></author-notes><pub-date pub-type="epreprint"><day>25</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><day>21</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2018</year></pub-date><volume>38</volume><issue>6</issue><elocation-id>BSR20180694</elocation-id><history><date date-type="received"><day>07</day><month>5</month><year>2018</year></date><date date-type="rev-recd"><day>07</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#169; 2018 The Author(s).</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bsr-38-bsr20180694.pdf"/><abstract><p><bold>Introduction:</bold> Association between Cyclin D1 (CCND1) single nucleotide polymorphism (SNP) rs9344 and cancer risk is paradoxical. Thus, we performed a meta-analysis to explore the association between <italic>CCND1</italic> variant and overall cancer risk in Indian population. <bold>Methods:</bold> Data from 12 published studies including 3739 subjects were collected using <italic>Pubmed</italic> and <italic>Embase. RevMan (Review Manager) 5.3</italic> was used to perform the meta-analysis. OR with 95%CI were calculated to establish the association. <bold>Results:</bold> Overall, the cumulative findings demonstrated that <italic>CCND1</italic> polymorphism (rs9344) was not significantly associated with cancer risk in all the genetic models studied (dominant model: GG vs GA+AA: OR (95%CI) = 0.81 (0.60&#8211;1.09), <italic>P</italic>=0.17; recessive model: GG+GA vs AA: OR (95%CI) = 1.23 (0.96&#8211;1.59), <italic>P</italic>=0.11; co-dominant model: <bold>GG vs AA: OR (95%CI) = 1.35 (0.93&#8211;1.97), <italic>P</italic>=0.12;</bold> co-dominant model: <bold>(GG vs GA: OR (95%CI) = 1.16 (0.85&#8211;1.59), <italic>P</italic>=0.34</bold>; allelic model: A vs G: OR (95%CI) = 1.20 (1.14&#8211;2.85), <italic>P</italic>=0.23; allelic model: G vs A: OR (95%CI) = 0.83 (0.62&#8211;1.12), <italic>P</italic>=0.23). Subgroup analysis according to cancer types presented significant association of <italic>CCND1</italic> polymorphism and increased breast cancer risk in dominant model (GG vs GA+AA: OR = 2.75, 95%CI = 1.54&#8211;4.90, <italic>P</italic>=0.0006) and allelic model (G vs A: OR = 1.63, 95%CI = 1.22&#8211;2.19, <italic>P</italic>=0.001). An increased esophageal cancer risk in recessive model (GG+GA vs AA: OR = 1.51, 95%CI = 1.05&#8211;2.16, <italic>P</italic>=0.03) and co-dominant model (GG vs AA: OR = 2.51, 95%CI = 1.10&#8211;5.71, <italic>P</italic>=0.03) was detected. A higher risk for colorectal cancer was detected under both the co-dominant models (GG vs AA: OR = 2.46, 95%CI = 1.34&#8211;4.51, <italic>P</italic>=0.004 and GG vs GA: OR = 1.74, 95%CI = 1.14&#8211;2.67, <italic>P</italic>=0.01). However, in case of cervical cancer risk a non-significant association was reported under the recessive model (GG+GA vs AA: OR = 1.52, 95%CI = 0.60&#8211;3.90, <italic>P</italic>=0.38) with reference to <italic>CCND1</italic> polymorphism (rs9344). The trial sequential analysis (TSA) showed that the cumulative Z-curve neither crossed the trial sequential monitoring boundary nor reached the required information size (RIS). Thus, present meta-analysis remained inconclusive due to insufficient evidence. <bold>Conclusion:</bold>
<italic>CCND1</italic> polymorphism rs9344 may not have a role in overall cancer susceptibility in Indian population. However, this polymorphism acts as a crucial risk factor for breast, esophageal, and colorectal cancer but not for cervical cancer. Future studies with larger sample size are required to draw a reliable conclusion.</p></abstract><kwd-group><kwd>CCND1</kwd><kwd>G870A</kwd><kwd>India</kwd><kwd>Meta-analysis</kwd><kwd>Polymorphism</kwd><kwd>rs9344</kwd></kwd-group><counts><page-count count="17"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Cancer is a major global health problem and it is worse in case of low- and middle-income developing countries. According to India&#8217;s National Cancer Registry Program (NCRP), 1.45 million cases would occur in 2016 with 0.74 million deaths in India. This is expected to rise to 1.73 million cases and 0.88 million deaths in 2020 [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. Cancer is considered the disease of abnormal cell division. Besides, many environmental cofactors (smoking, use of alcohol, exposure to UV radiations, infections with certain viruses) and host genetic makeup has been recognized as a pivotal risk factor for human cancers.</p><p>India ranks third in the world in terms of incidence rate of cancer cases amongst women after China and the U.S.A. According to the Globocan report 2012, there were &#8764;232000 breast cancer cases registered in the U.S.A., however in India, 145000 new cases were reported. The burden of breast cancer in India is approximately two-thirds of that of the U.S.A. and is growing progressively [<xref rid="B3" ref-type="bibr">3</xref>]. Breast cancer is one of the most common malignancies in women worldwide, and each year more than 1 million new cases are diagnosed [<xref rid="B4" ref-type="bibr">4</xref>]. The main risk factors for breast cancer are genetic predisposition, lifestyle, and environment [<xref rid="B5" ref-type="bibr">5&#8211;7</xref>]. Genetic polymorphisms have been identified as one of the crucial factor for determining inter-individual susceptibility to cancer [<xref rid="B8" ref-type="bibr">8</xref>]. The clinical importance of <italic>CCND1</italic> gene lies in the fact that 5&#8211;20% of breast cancer cases present with either amplified or deleted version of the gene [<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>]. <italic>CCND1</italic> also has documented oncogenic characteristics by manipulating the regulation of cell cycle machinery particularly at the transition phase of G<sub>1</sub>/S [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>]. Cyclin D1 (CCND1) protein is found to be overexpressed in more than 50% of breast cancer cases [<xref rid="B13" ref-type="bibr">13</xref>]. An important functional single nucleotide polymorphism (SNP) in <italic>CCND1</italic> gene (rs9344) G870A, may influence the breast cancer development [<xref rid="B14" ref-type="bibr">14</xref>]. Esophageal cancer is the eighth most common cancer overall. In 2012, worldwide, 456000 new cases have been estimated (3.2% of all incidence cancer cases). It is the sixth most common cause of death from cancer, with an estimated 400000 deaths in 2012 (4.9% of all cancer deaths) [<xref rid="B3" ref-type="bibr">3</xref>]. It is one of the most common and lethal type of cancer worldwide, with &lt;20% of 5-year survival rate [<xref rid="B15" ref-type="bibr">15</xref>]. Colorectal cancer is the third most commonly diagnosed cancer in men and second in women, with &gt;1.4 million new cases annually [<xref rid="B16" ref-type="bibr">16</xref>]. Geographical deviation in the incidence rates has been observed as developed world contributes to &gt;50% of the cases. Though, mortality is more in the developing countries due to insufficient resources and health infrastructure [<xref rid="B17" ref-type="bibr">17</xref>]. In India, the age standardized rate (ASR) for colorectal cancer is 7.2 per 100000 men and 5.1 per 100000 women [<xref rid="B3" ref-type="bibr">3</xref>].</p><p><italic>CCND1</italic> is a key cell cycle regulatory gene which governs the G<sub>1</sub>/S checkpoint in cell cycle. It is one of the most frequently altered molecules in human carcinogenesis. A common G/A SNP [dbSNP ID rs9344] was first described by Betticher et al. (1995) [<xref rid="B18" ref-type="bibr">18</xref>]. This SNP rs9344 is located at codon 242 in the exon-4/intron boundary of <italic>CCND1</italic> and responsible for alternate splicing of transcripts with different half-lives [<xref rid="B18" ref-type="bibr">18</xref>]. Since then many case&#8211;control studies have been conducted to explore the potential association between <italic>CCND1</italic> SNP (rs9344) and cancer susceptibility. Occurrence of this nucleotide variation has been found to be coupled with the risk of various cancers including cervical, breast, oral, esophageal, lung, urinary bladder, prostate, and colorectal [<xref rid="B19" ref-type="bibr">19&#8211;29</xref>]. The outcomes of these studies were inconsistent in different ethnic groups. To overcome this conflict, several meta-analyses have been performed worldwide to see the effect of <italic>CCND1</italic> polymorphism and risk for different types of cancer [<xref rid="B30" ref-type="bibr">30&#8211;35</xref>]. To the best of our knowledge, no report is available from India addressing the impact of <italic>CCND1</italic> SNP and overall cancer risk. Hence, we aimed to investigate the role of <italic>CCND1</italic> polymorphism G870A (rs9344) in overall cancer susceptibility amongst Indian population by conducting this meta-analysis. The present data could be helpful in enriching the existing knowledge with respect to involvement of <italic>CCND1</italic> polymorphism and cancer susceptibility in Indian population.</p></sec><sec sec-type="methods" id="sec2"><title>Methods</title><sec id="sec2-1"><title>Literature search strategy</title><p><italic>Pubmed</italic> and <italic>Embase</italic> databases were searched with the keywords &#8216;<italic>CCND1</italic>&#8217;, &#8216;Cyclin D1&#8217;, &#8216;SNP&#8217;, &#8216;cancer&#8217;, &#8216;India&#8217;, and &#8216;polymorphism&#8217; for literature published till September 2016. All studies included in the present meta-analysis met the following inclusion and exclusion criteria.</p></sec><sec id="sec2-2"><title>Inclusion criteria</title><p>(i) Prospective or case&#8211;control studies involving association analysis between <italic>CCND1</italic> SNP G870A (rs9344) and cancer susceptibility, (ii) studies included Indian population, (iii) genotypic and allelic details are provided for both the cases and control groups, (iv) full text available, and (v) articles published in English language.</p></sec><sec id="sec2-3"><title>Exclusion criteria</title><p>(i) Studies published on populations other than Indian, (ii) articles published in languages except English, and (iii) articles not providing genotypic and allelic details.</p></sec><sec id="sec2-4"><title>Data retrieval</title><p>Data from all eligible studies were retrieved independently by two investigators (N.T. and S.K.). The retrieved data incorporated the following details: (i) PubMed IDentifier (PMID), (ii) name of the first author, (iii) year of publication, (iv) country, (v) sources of controls, (vi) methods for genotyping, and (vii) frequency of genotypic and allelic data.</p></sec><sec id="sec2-5"><title>Quality assessment</title><p>Quality of the included studies was assessed by assigning the quality scores as previously mentioned by He et al. (2014) [<xref rid="B36" ref-type="bibr">36</xref>]. The scores were assigned to each qualified studies between 0 and 10. Studies with &gt;5 scores were included for the further analyses (Supplementary Table S1).</p></sec><sec id="sec2-6"><title>Meta-analysis</title><p>RevMan (<italic>Review Manager)</italic> is an easy tool to perform the meta-analyses and generate the graphs (forest plot, funnel plot) in publication standard. Meta-analysis of <italic>CCND1</italic> gene G870A polymorphism (rs9344) was performed by <italic>RevMan 5.3</italic> [<xref rid="B37" ref-type="bibr">37</xref>]<italic>.</italic> For statistical models, both fixed model and random model were included in the RevMan. For random models, DerSimonian and Laird random-effects models were used. Odds ratios (ORs) with 95% confidence intervals (95%CIs) were used to assess the strength of association between the <italic>CCND1</italic>-G870A polymorphisms and cancer risk. The pooled OR was evaluated by the Z-test and a <italic>P</italic>-value &lt;0.05 suggests a significant association.</p><p><italic>I<sup>2</sup></italic> was used to estimate total variation across studies due to heterogeneity in percentage. A percentage of &lt;25% was considered as a low level of heterogeneity, 25&#8211;50% as a moderate level of heterogeneity, and &gt;50% as a high level of heterogeneity. <italic>I<sup>2</sup></italic>&gt; 50% could suggest heterogeneity and suggest using a random-effect estimate [<xref rid="B38" ref-type="bibr">38</xref>]. Otherwise, the fixed-effect model was used to calculate pooled ORs [<xref rid="B39" ref-type="bibr">39</xref>].</p><p>Software RevMan 5.3 used in this meta-analysis is freely available at <ext-link ext-link-type="uri" xlink:href="http://community.cochrane.org/tools/review-production-tools/revman-5/revman-5-download">http://community.cochrane.org/tools/review-production-tools/revman-5/revman-5-download</ext-link></p></sec><sec id="sec2-7"><title>Statistical analysis</title><p>The association between <italic>CCND1</italic> polymorphism and cancer risk was analyzed by OR with 95%CI in different genetic models: dominant (GA+AA vs GG), recessive (AA vs GG+GA), co-dominant (GA vs GG and AA vs GG), and allelic (A vs G and G vs A). The <italic>P</italic>-value &lt;0.05 was considered statistically significant. Subgroup analysis was done after stratification of data according to various cancer types.</p><p>Heterogeneity was calculated by chi-square test and the extent of heterogeneity was measured by the value of <italic>I<sup>2</sup></italic> statistic. The OR of different types of genetic models was evaluated by employing the fixed-effect model (when <italic>I<sup>2</sup></italic> &lt; 50%) or random-effect model (when <italic>I<sup>2</sup></italic> &gt; 50%). Egger&#8217;s bias test and Begg&#8217;s funnel plot was used to assess the publication bias [<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>]. It is a well-acknowledged fact that meta-analyses are vulnerable to random errors due to sparse data and repetitive testing of accrued data [<xref rid="B42" ref-type="bibr">42</xref>]. Hence, trial sequential analysis (TSA) was performed to minimize the type I error and random error as the present study had smaller sample size. TSA was performed as described previously by Fu et al. (2017) [<xref rid="B43" ref-type="bibr">43</xref>]. It was done by using TSA software version 0.9.5.10. (<ext-link ext-link-type="uri" xlink:href="http://www.ctu.dk/tsa/">http://www.ctu.dk/tsa/</ext-link>) [<xref rid="B44" ref-type="bibr">44</xref>] to calculate the required information size (RIS) (meta-analysis sample size) by taking the control event proportion to 25.77%, experimental event proportion 21.55%, a relative risk reduction (RRR) 10%, power 80%, and type I error (&#945;) 5%. The monitoring boundaries were constructed to determine whether present meta-analysis is sufficiently powered and conclusive. Therefore, it is able to reject false-positive reports from meta-analysis [<xref rid="B45" ref-type="bibr">45</xref>]. If the Z-curve crosses the TSA boundaries or futility area, there is sufficient information to support the conclusions and further trials are unlikely to change the findings. If the Z-curve does not cross the any of the boundaries or reach the RIS, evidence is insufficient to reach a firm conclusion.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1"><title>Study characteristics</title><p>Using the <italic>Pubmed</italic> and <italic>Embase</italic> database, a total of 12 studies were searched independently by two investigators (S.K. and N.T.) according to the methodology depicted in flow diagram (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Methodology flowchart for the selection of studies in the present meta-analysis</title><p>*Since, data from study PMID 24604328 were extracted twice, hence total articles mentioned are 12 in the text.</p></caption><graphic xlink:href="bsr-38-bsr20180694-g1"/></fig><p>Data from one study with PMID 24604328 was extracted twice. All the 12 studies including 1791 cancer cases and 1948 controls met our inclusion criteria. The characteristics of included studies for the present meta-analysis from different cancers are presented in <xref rid="T1" ref-type="table">Table 1</xref>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of the studies included in the meta-analysis</title></caption><table-wrap-foot><fn id="req-154269571326426380"><p>Abbreviation: RFLP, restriction fragment length polymorphism. *PMID24604328 taken twice.</p></fn></table-wrap-foot></table-wrap><p>Details of genotypic and allelic frequencies of <italic>CCND1</italic> polymorphism is shown in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Distribution of CCND1-G870A genotypes and allelic frequency in cancer cases and controls</title></caption><table-wrap-foot><fn id="T2TFN1"><label>*</label><p>PMID: 24604328 repeated twice in our study. NA, not available.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-2"><title>Meta-analysis of CCND1 G/A polymorphism (rs9344)</title><p>A total of 12 studies were included in the analysis to evaluate the association between <italic>CCND1</italic> polymorphism and cancer risk in Indian population. The results from meta-analysis of the association between <italic>CCND1</italic> polymorphism (rs9344) and cancer risk in 12 case&#8211;control studies are shown in <xref ref-type="fig" rid="F2">Figure 2</xref> and&#160;<xref rid="T3" ref-type="table">Table 3</xref>. Values of ORs with 95%CI were as follows: dominant model (GG vs GA+AA: OR = 0.81, 95%CI = 0.60&#8211;1.09, <italic>P</italic>=0.17, <italic>I<sup>2</sup></italic>= 72%); recessive model (GG+GA vs AA: OR = 1.23, 95%CI = 0.96&#8211;1.59, <italic>P</italic>=0.11, <italic>I<sup>2</sup></italic> = 64%); co-dominant model (GG vs AA: OR = 1.35, 95%CI = 0.93-1.97, P = 0.12, I<sup>2</sup> = 72%); co-dominant model (GG vs GA: OR = 1.16, 95%CI = 0.85&#8211;1.59, <italic>P</italic>=0.34, <italic>I<sup>2</sup></italic> = 69%); allele model (A vs G: OR = 1.20, 95%CI = 1.14&#8211;2.85, <italic>P</italic>=0.23, <italic>I<sup>2</sup></italic> = 82%), and allele model (G vs A: OR = 0.83, 95%CI = 0.62&#8211;1.12, <italic>P</italic>=0.23, <italic>I<sup>2</sup></italic> = 82%) (<xref rid="T3" ref-type="table">Table 3</xref>). If the values of <italic>I<sup>2</sup></italic> were &gt;50% then the random-effect model was applied, otherwise fixed-effect model was used to calculate the pooled ORs and 95%CI. In meta-analysis, <italic>P<sup>Z</sup></italic>&lt;0.05 was considered statistically significant. Here, we demonstrate that <italic>CCND1</italic> polymorphism G870A (rs9344) is not associated with the risk for overall cancers in Indian population.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Forest plots describing the association of <italic>CCND1</italic>-G870A polymorphism with overall cancer risk</title><p>(<bold>A</bold>) dominant model (GG vs GA+AA); (<bold>B</bold>) recessive model (GG+GA vs AA); (<bold>C</bold>) co-dominant model (GG vs GA); (<bold>D</bold>) co-dominant model (GG vs AA); (<bold>E</bold>) allele model (A vs G); (<bold>F</bold>) allele model (G vs A).</p></caption><graphic xlink:href="bsr-38-bsr20180694-g2a"/><graphic xlink:href="bsr-38-bsr20180694-g2b"/></fig><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Meta-analysis results based on different genetic models</title></caption><table-wrap-foot><fn><p>Abbreviations: P<sup>H</sup>, P value for heterogeneity; P<sup>Z</sup>, P value for Z-test.</p></fn></table-wrap-foot></table-wrap><p>On subgroup analysis stratified according to cancer types showed significant association of <italic>CCND1</italic> polymorphism and increased breast cancer risk in dominant model (GG vs GA+AA: OR = 2.75, 95%CI = 1.54&#8211;4.90, <italic>P</italic>=0.0006), allelic model (G vs A: OR = 1.63, 95%CI = 1.22&#8211;2.19, <italic>P</italic>=0.001). A statistically significant association with esophageal cancer risk was observed in recessive (GG+GA vs AA: OR = 1.51, 95%CI = 1.05&#8211;2.16, <italic>P</italic>=0.03) and co-dominant model (GG vs AA: OR = 2.51, 95%CI = 1.10&#8211;5.71, <italic>P</italic>=0.03). An increased risk for colorectal cancer was detected under both the co-dominant models (GG vs AA: OR = 2.46, 95%CI = 1.34&#8211;4.51, <italic>P</italic>=0.004 and GG vs GA: OR = 1.74, 95%CI = 1.14&#8211;2.67, <italic>P</italic>=0.01). Contrary to this, none of the genetic model reported a statistically significant association with cervical cancer risk. Although a non-significant association was observed in recessive model (GG+GA vs AA: OR = 1.52, 95%CI = 0.60&#8211;3.90, <italic>P</italic>=0.38) and co-dominant model (GG vs AA: OR = 1.45, 95%CI = 0.55&#8211;3.85, <italic>P</italic>=0.46) with reference to <italic>CCND1</italic> polymorphism (rs9344) (<xref ref-type="fig" rid="F3">Figures 3</xref>&#8211;<xref ref-type="fig" rid="F6">6</xref> and&#160;<xref rid="T4" ref-type="table">Table 4</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Forest plots describing the association of <italic>CCND1</italic>-G870A polymorphism with breast cancer risk</title><p>(<bold>A</bold>) dominant model (GG vs GA+AA); (<bold>B</bold>) recessive model (GG+GA vs AA); (<bold>C</bold>) co-dominant model (GG vs GA); (<bold>D</bold>) co-dominant model (GG vs AA); (<bold>E</bold>) allele model (A vs G); (<bold>F</bold>) allele model (G vs A).</p></caption><graphic xlink:href="bsr-38-bsr20180694-g3a"/><graphic xlink:href="bsr-38-bsr20180694-g3b"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Forest plots describing the association of <italic>CCND1-G870A</italic> polymorphism with colorectal cancer risk</title><p>(<bold>A</bold>) dominant model (GG vs GA+AA); (<bold>B</bold>) recessive model (GG+GA vs AA); (<bold>C</bold>) co-dominant model (GG vs GA); (<bold>D</bold>) co-dominant model (GG vs AA).</p></caption><graphic xlink:href="bsr-38-bsr20180694-g4"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Forest plots describing the association of <italic>CCND1</italic>-G870A polymorphism with esophageal cancer risk</title><p>(<bold>A</bold>) dominant model (GG vs GA+AA); (<bold>B</bold>) recessive model (GG+GA vs AA); (<bold>C</bold>) co-dominant model (GG vs GA); (<bold>D</bold>) co-dominant model (GG vs AA).</p></caption><graphic xlink:href="bsr-38-bsr20180694-g5"/></fig><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Forest plots describing the association of <italic>CCND1</italic>-G870A polymorphism with cervical cancer risk</title><p>(<bold>A</bold>) dominant model (GG vs GA+AA); (<bold>B</bold>) recessive model (GG+GA vs AA) (<bold>C</bold>) co-dominant model (GG vs GA); (<bold>D</bold>) co-dominant model (GG vs AA).</p></caption><graphic xlink:href="bsr-38-bsr20180694-g6"/></fig><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Subgroup analysis: meta-analysis results according to the type of cancer</title></caption><table-wrap-foot><fn><p>Abbreviations: <italic>P<sup>Z</sup>, P</italic>-value for Z-test; <italic>P<sup>H</sup>, P</italic>-value for heterogeneity. Statistically significant values shown in bold.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-3"><title>Heterogeneity measurement</title><p>Heterogeneity value depicted as <italic>I<sup>2</sup></italic> was calculated for different genetic models and presented in <xref rid="T3" ref-type="table">Table 3</xref>. Heterogeneity was observed in all the genotypic and allelic models. For dominant model: GG vs GA+AA: <italic>I<sup>2</sup></italic> = 72%, <italic>P</italic> for heterogeneity &lt;0.0001; recessive model: GG+GA vs AA: <italic>I<sup>2</sup></italic> = 64%, <italic>P</italic> for heterogeneity = 0.001; co-dominant model: GG vs AA: <italic>I<sup>2</sup></italic> = 69%, <italic>P</italic> for heterogeneity = 0.0002; co-dominant model: GG vs GA: <italic>I<sup>2</sup></italic> = 72%, <italic>P</italic> for heterogeneity = 0.0001; allelic model: A vs G: <italic>I<sup>2</sup></italic> = 82%, <italic>P</italic> for heterogeneity &lt;0.00001 and allelic model: G vs A: <italic>I<sup>2</sup></italic> = 82%, <italic>P</italic> for heterogeneity &lt;0.00001 were noted, respectively (<xref rid="T3" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3-4"><title>Publication bias</title><p>Funnel plots were used in random-effect and fixed-effect models respectively to detect the publication bias. A relatively symmetric distribution in the funnel plot was observed, which indicates that there is no significant publication bias in the included studies (<xref ref-type="fig" rid="F7">Figure 7</xref>).</p><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>Funnel plot assessing publication bias in recessive model (GG+GA vs AA)</title></caption><graphic xlink:href="bsr-38-bsr20180694-g7"/></fig></sec><sec id="sec3-5"><title>TSA</title><p>The TSA for association between CCND1 polymorphism (rs9344) and overall cancer risk showed that only conventional boundary was crossed by Z-curve, however, it neither crossed the TSA boundary nor the futility area. And the total sample size (3739) did not reach the RIS (11375) (<xref ref-type="fig" rid="F8">Figure 8</xref>). This result indicates that present meta-analysis is inconclusive at this level. Further studies/trials are needed to make this association valid.</p><fig id="F8" orientation="portrait" position="float"><label>Figure 8</label><caption><title>TSA of association of <italic>CCND1</italic> polymorphism (rs9344) and overall cancer risk in Indian population from 12 studies</title><p>The cumulative Z-curve was constructed by using random-effect model. We calculated &#945;-spending adjusted RIS of 11375 patients using &#945; = 0.05 (two-sided), &#946; = 0.20 (power = 80%). <italic>Note: Z-curve (blue); Conventional boundary (green); TSA boundary (red)</italic>.</p></caption><graphic xlink:href="bsr-38-bsr20180694-g8"/></fig></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p><italic>CCND1</italic> is key driver of normal cell cycle regulation and genetic variation in this gene has been reported in many types of cancers. A SNP G870A (rs9344) located on exon-4&#8211;intron boundary of <italic>CCND1</italic> has been studied extensively in several cancer types. Several reports from different parts of the world have been published with reference to <italic>CCND1</italic> polymorphism and risk of various types of cancers including cervical, prostate, colorectal, urinary bladder, squamous cell carcinoma of the head and neck etc. [<xref rid="B46" ref-type="bibr">46&#8211;50</xref>]. Investigators from India also tried to explore the association of CCND1 polymorphism and susceptibility to different cancer types including cervical, breast, oral, esophageal, lung, urinary bladder, prostate, and colorectal [<xref rid="B19" ref-type="bibr">19&#8211;29</xref>]. However, these reports are conflicting thus we performed meta-analysis on the literature available in order to provide more accurate information on the role of <italic>CCND1</italic> G870A (rs9344) polymorphism and overall cancer risk in Indian population. Although, various meta-analyses on individual cancer susceptibility have been published globally [<xref rid="B30" ref-type="bibr">30&#8211;35</xref>]. Pabalan et al. (2008) [<xref rid="B51" ref-type="bibr">51</xref>], performed a meta-analysis on role of <italic>CCND1</italic> polymorphism in different types of cancers and populations. However, a comprehensive data are lacking from India with overall cancer risk. Hence, we have designed the present study focussed on Indian population.</p><p>The present meta-analysis, contained a total of 12 studies comprising 1791 cancer cases and 1948 controls [<xref rid="B19" ref-type="bibr">19&#8211;29</xref>] showed the lack of significant association between <italic>CCND1</italic> G870A polymorphism (rs9344) and overall cancer risk in all the genetic models. These findings are consistent with the result of another study by Luo et al. (2016) [<xref rid="B52" ref-type="bibr">52</xref>], which ruled out the involvement of <italic>CCND1</italic> polymorphism (G870A) with the risk of hepatocellular carcinoma. In the similar lines, study by Zheng et al. (2015) [<xref rid="B53" ref-type="bibr">53</xref>] suggested that <italic>CCND1</italic> polymorphism may not be associated with the risk of prostate cancer. Similarly, Wang et al. (2018) [<xref rid="B54" ref-type="bibr">54</xref>] also found no significant association between the let-7i rs10877887 and let-7a-1/let-7f-1/let-7d rs13293512 polymorphisms and overall cancer risk. In disagreement with our findings a meta-analysis by Pabalan et al. (2008) [<xref rid="B51" ref-type="bibr">51</xref>], showed an increased cancer risk associated with <italic>CCND1</italic>-A870G polymorphism in the human population. Another study by Qin et al. (2014) [<xref rid="B55" ref-type="bibr">55</xref>] also indicated that <italic>CCND1</italic> polymorphism may increase the risk of non-Hodgkin lymphoma but it was not true in case of leukemia. On the identical lines, Lin et al. (2014) [<xref rid="B56" ref-type="bibr">56</xref>] too observed the lack of association between <italic>CCND1</italic> polymorphism (G870A) and head and neck cancer, however; they found that smokers carrying &#8216;A&#8217; allele or &#8216;AA&#8217; genotype for rs9344 SNP located on <italic>CCND1</italic> may be at higher risk to head and neck cancer development.</p><p>Our subgroup analysis showed an increased risk (1.52-fold) for cervical cancer development but this association could not attain the limits of statistical significance (<italic>P</italic>=0.38). The possible explanation for this observation may be the small sample size of contributing studies. No promising association of this SNP has been established with the development of cervical cancer in Caucasian population by Yang et al. (2015) [<xref rid="B57" ref-type="bibr">57</xref>]. In another study, no significant association was reported between the <italic>CCND1</italic> SNP (rs9344) and overall risk for cervical cancer in the Asian population but on stratification analysis by race, individuals carrying the AA or AA/AG genotypes showed a significant higher risk in comparison with GG carriers [<xref rid="B32" ref-type="bibr">32</xref>]. In parallel to the findings from the present study, Hu et al. (2014) [<xref rid="B30" ref-type="bibr">30</xref>], also did not find the association of <italic>CCND1</italic> G870A polymorphism and cervical cancer risk amongst different ethnic groups including Asian, Caucasian, and mixed in a cumulative meta-analysis.</p><p>Additionally, a significant association between <italic>CCND1</italic> polymorphism and increased risk for breast and esophageal cancer has been established. Similar to our results, Sergentanis and Economopoulos (2011) [<xref rid="B58" ref-type="bibr">58</xref>] found that the &#8216;A&#8217; allele of the <italic>CCND1</italic> G870A polymorphism is associated with higher risk for breast cancer. These findings are further strengthened by another meta-analyses conducted by Lu et al. (2009) [<xref rid="B59" ref-type="bibr">59</xref>] and Cui et al. (2012) [<xref rid="B60" ref-type="bibr">60</xref>] that showed the association of AA genotype of <italic>CCND1</italic> G870A polymorphism with breast cancer susceptibility. Similarly, Soleimani et al. (2016) [<xref rid="B61" ref-type="bibr">61</xref>] showed a significant association between <italic>CCND1</italic> G870A polymorphism and breast cancer risk but in Caucasians. A meta-analysis conducted Wen et al. (2014) [<xref rid="B62" ref-type="bibr">62</xref>] supported our data that <italic>CCND1</italic> G870A polymorphism is a potential risk factor in the development of esophageal cancer. Other related meta-analysis by Cai et al. (2013) [<xref rid="B63" ref-type="bibr">63</xref>] is not in agreement with our findings and showed lack of potential association between <italic>CCND1</italic> G870A polymorphism and esophageal cancer risk. Likewise, Tang et al. (2015) [<xref rid="B64" ref-type="bibr">64</xref>], also observed similar results describing that <italic>CCND1</italic> SNP rs9344 is not having role in esophageal squamous cell carcinoma.The present study suggests that there is a significant correlation between this polymorphism and increased risk of colorectal cancer amongst Indian population. Recently, Xu et al. (2016) [<xref rid="B34" ref-type="bibr">34</xref>] suggested that this SNP may increase the risk for developing colorectal cancer with special emphasis to sporadic colorectal cancer in Caucasian population. The study by Jiang et al. (2006) [<xref rid="B65" ref-type="bibr">65</xref>] suggested that the <italic>CCND1</italic> G870 AA genotype may increase the colorectal cancer risk compared with the GG+AG genotype (OR = 1.56, 95%CI = 1.10&#8211;2.21) in an Indian population. Similarly, Zhang et al. (2016) [<xref rid="B33" ref-type="bibr">33</xref>], suggested that <italic>CCND1</italic> polymorphism is a risk factor for gastric cancer in Caucasians. According to the literature search, Dai et al. (2016) [<xref rid="B35" ref-type="bibr">35</xref>] also tried to establish the association between <italic>CCND1</italic> polymorphism (rs678653) located on the 3&#8242;-UTR and susceptibility to cancer, but they have not studied the polymorphism under investigation G870A (rs9344).</p><p>The present study had some limitations, first, all of the included studies were hospital based which may not represent the true population. Second, environmental factors like smoking, use of alcohol, and infections with viruses were not included in the present meta-analysis. Finally, the sample size was reasonably small, which may be the reason for controversial results.</p></sec><sec sec-type="conclusion" id="sec5"><title>Conclusion</title><p>In conclusion, present meta-analysis showed that <italic>CCND1</italic> SNP (rs9344) may not serve as a risk factor for overall cancer susceptibility in Indian population. However, a significant association between <italic>CCND1</italic> SNP and increased risk for breast, esophageal, and colorectal cancer was found on subgroup analysis. Moreover, a non-significant increased risk for cervical cancer in relation to <italic>CCND1</italic> polymorphism was observed in Indian population. Thus, <italic>CCND1</italic> G870A (rs9344) polymorphism has a potential to be served as a prognostic biomarker for breast, esophageal, and colorectal cancer in Indian population. Still, larger and well-designed studies including other risk factors are warranted in future to validate the findings from present analysis.</p></sec><sec sec-type="supplementary-material" id="sec6"><title>Supporting information</title><table-wrap id="T5" orientation="portrait" position="float"><label>Table S1</label><caption><title>Quality assessment scoring of included studies in the Meta-analysis.</title></caption><media mimetype="pdf" xlink:href="bsr20180694_Supp1.pdf" orientation="portrait" id="d35e2384" position="anchor"/></table-wrap></sec></body><back><sec id="sec7" sec-type="author-contrib"><title>Author contribution</title><p>NT: study design, literature survey, data extraction, analysis, interpretation of the results, manuscript writing. SK: literature survey, data extraction, analysis. RM: critically reviwed the manuscript.</p></sec><sec id="sec8" sec-type="COI-statement"><title>Competing interests</title><p>The authors declare that there are no competing interests associated with the manuscript.</p></sec><sec id="sec9" sec-type="funding"><title>Funding</title><p>The present study was not funded by any agency. Open access charges provided by the Institutional funds of NICPR (ICMR) Noida.</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term><italic>CCND1</italic></term><def><p>cyclin D1</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>PMID</term><def><p>PubMed IDentifier</p></def></def-item><def-item><term>RevMan</term><def><p><italic>Review Manager</italic></p></def></def-item><def-item><term>RIS</term><def><p>required information size</p></def></def-item><def-item><term>SNP</term><def><p>single nucleotide polymorphism</p></def></def-item><def-item><term>TSA</term><def><p>trial sequential analysis</p></def></def-item><def-item><term>95%CI</term><def><p>95% confidence interval</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><mixed-citation publication-type="other"><comment>The National Center for Disease Informatics and Research <ext-link ext-link-type="uri" xlink:href="http://www.ncdirindia.org">http://www.ncdirindia.org</ext-link> [Accessed: 24 November 2018]</comment></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>A.K</given-names></name>, <name><surname>Kumar</surname><given-names>P.</given-names></name>, <name><surname>Bhandari</surname><given-names>M.</given-names></name>, <name><surname>Devnani</surname><given-names>B.</given-names></name> and <name><surname>Rath</surname><given-names>G.K.</given-names></name></person-group> (<year>2016</year>) <article-title>Burden of preventable cancers in India: time to strike the cancer epidemic</article-title>. <source>J. Egypt. Natl. Cancer Inst.</source>, <volume>29</volume>, <fpage>11</fpage>&#8211;<lpage>18</lpage>, <comment>PMID: 27591115</comment></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="other">, <comment>Globocan report 2012 <ext-link ext-link-type="uri" xlink:href="http://globocan.iarc.fr/Default.aspx">http://globocan.iarc.fr/Default.aspx</ext-link> [Accessed: 24 November 2018]</comment></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makki</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>) <article-title>Diversity of breast carcinoma: histological subtypes and clinical relevance</article-title>. <source>Clin. Med. Insights Pathol.</source>
<volume>8</volume>, <fpage>23</fpage>&#8211;<lpage>31</lpage>
<pub-id pub-id-type="doi">10.4137/CPath.S31563</pub-id>
<?supplied-pmid 26740749?><pub-id pub-id-type="pmid">26740749</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabris</surname><given-names>V.T.</given-names></name></person-group> (<year>2014</year>) <article-title>From chromosomal abnormalities to the identification of target genes in mouse models of breast cancer</article-title>. <source>Cancer Genet.</source>
<volume>207</volume>, <fpage>233</fpage>&#8211;<lpage>246</lpage>
<pub-id pub-id-type="doi">10.1016/j.cancergen.2014.06.025</pub-id>
<?supplied-pmid 25176624?><pub-id pub-id-type="pmid">25176624</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.M.</given-names></name> and <name><surname>Lin</surname><given-names>S.S.</given-names></name></person-group> (<year>2000</year>) <article-title>Dietary fat and breast cancer</article-title>. <source>Annu. Rev. Nutr.</source>
<volume>20</volume>, <fpage>221</fpage>&#8211;<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.nutr.20.1.221</pub-id>
<?supplied-pmid 10940333?><pub-id pub-id-type="pmid">10940333</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strumylait&#279;</surname><given-names>L.</given-names></name>, <name><surname>Mechono&#353;ina</surname><given-names>K.</given-names></name> and <name><surname>Tama&#353;auskas</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>) <article-title>Environmental factors and breast cancer</article-title>. <source>Medicina (Kaunas)</source>
<volume>46</volume>, <fpage>867</fpage>&#8211;<lpage>873</lpage>
<pub-id pub-id-type="doi">10.3390/medicina46120121</pub-id>
<?supplied-pmid 21532292?><pub-id pub-id-type="pmid">21532292</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodoropoulos</surname><given-names>G.E.</given-names></name>, <name><surname>Michalopoulos</surname><given-names>N.V.</given-names></name>, <name><surname>Pantou</surname><given-names>M.P.</given-names></name>, <name><surname>Kontogianni</surname><given-names>P.</given-names></name>, <name><surname>Gazouli</surname><given-names>M.</given-names></name>, <name><surname>Karantanos</surname><given-names>T.</given-names></name></person-group>
<etal/> (<year>2012</year>) <article-title>Caspase 9 promoter polymorphisms confer increased susceptibility to breast cancer</article-title>. <source>Cancer Genet.</source>
<volume>205</volume>, <fpage>508</fpage>&#8211;<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1016/j.cancergen.2012.08.001</pub-id>
<?supplied-pmid 22981751?><pub-id pub-id-type="pmid">22981751</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormandy</surname><given-names>C.J.</given-names></name>, <name><surname>Musgrove</surname><given-names>E.A.</given-names></name>, <name><surname>Hui</surname><given-names>R.</given-names></name>, <name><surname>Daly</surname><given-names>R.J.</given-names></name> and <name><surname>Sutherland</surname><given-names>R.L.</given-names></name></person-group> (<year>2003</year>) <article-title>Cyclin D1, EMS1 and 11q13 amplification in breast cancer</article-title>. <source>Breast Cancer Res. Treat.</source>
<volume>78</volume>, <fpage>323</fpage>&#8211;<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1023/A:1023033708204</pub-id>
<?supplied-pmid 12755491?><pub-id pub-id-type="pmid">12755491</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillett</surname><given-names>C.</given-names></name>, <name><surname>Fantl</surname><given-names>V.</given-names></name>, <name><surname>Smith</surname><given-names>R.</given-names></name>, <name><surname>Fisher</surname><given-names>C.</given-names></name>, <name><surname>Bartek</surname><given-names>J.</given-names></name>, <name><surname>Dickson</surname><given-names>C.</given-names></name></person-group>
<etal/> (<year>1994</year>) <article-title>Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining</article-title>. <source>Cancer Res.</source>
<volume>54</volume>, <fpage>1812</fpage>&#8211;<lpage>1817</lpage>
<?supplied-pmid 8137296?><pub-id pub-id-type="pmid">8137296</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldin</surname><given-names>V.</given-names></name>, <name><surname>Lukas</surname><given-names>J.</given-names></name>, <name><surname>Marcote</surname><given-names>M.J.</given-names></name>, <name><surname>Pagano</surname><given-names>M.</given-names></name> and <name><surname>Draetta</surname><given-names>G.</given-names></name></person-group> (<year>1993</year>) <article-title>Cyclin D1 is a nuclear protein required for cell cycle progression in G1</article-title>. <source>Genes Dev.</source>
<volume>7</volume>, <fpage>812</fpage>&#8211;<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1101/gad.7.5.812</pub-id>
<?supplied-pmid 8491378?><pub-id pub-id-type="pmid">8491378</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prall</surname><given-names>O.W.</given-names></name>, <name><surname>Rogan</surname><given-names>E.M.</given-names></name>, <name><surname>Musgrove</surname><given-names>E.A.</given-names></name>, <name><surname>Watts</surname><given-names>C.K.</given-names></name> and <name><surname>Sutherland</surname><given-names>R.L.</given-names></name></person-group> (<year>1998</year>) <article-title>C-Myc or cyclin D1 mimics estrogen effects on cyclin ECdk2 activation and cell cycle reentry</article-title>. <source>Mol. Cell. Biol.</source>
<volume>18</volume>, <fpage>4499</fpage>&#8211;<lpage>4508</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.18.8.4499</pub-id>
<?supplied-pmid 9671459?><pub-id pub-id-type="pmid">9671459</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>M.F.</given-names></name>, <name><surname>Sweeney</surname><given-names>K.J.</given-names></name>, <name><surname>Hamilton</surname><given-names>J.A.</given-names></name>, <name><surname>Sini</surname><given-names>R.L.</given-names></name>, <name><surname>Manning</surname><given-names>D.L.</given-names></name>, <name><surname>Nicholson</surname><given-names>R.I.</given-names></name></person-group>
<etal/> (<year>1993</year>) <article-title>Expression and amplification of cyclin genes in human breast cancer</article-title>. <source>Oncogene</source>
<volume>8</volume>, <fpage>2127</fpage>&#8211;<lpage>2133</lpage>
<?supplied-pmid 8336939?><pub-id pub-id-type="pmid">8336939</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.</given-names></name>, <name><surname>Dong</surname><given-names>J.</given-names></name>, <name><surname>Ma</surname><given-names>H.</given-names></name>, <name><surname>Jin</surname><given-names>G.</given-names></name>, <name><surname>Hu</surname><given-names>Z.</given-names></name>, <name><surname>Peng</surname><given-names>Y.</given-names></name></person-group>
<etal/> (<year>2008</year>) <article-title>
<italic>CCND1</italic> G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis</article-title>. <source>Breast Cancer Res. Treat.</source>
<volume>116</volume>, <fpage>571</fpage>&#8211;<lpage>575</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-008-0195-y</pub-id>
<?supplied-pmid 18819000?><pub-id pub-id-type="pmid">18819000</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A.</given-names></name>, <name><surname>Siegel</surname><given-names>R.</given-names></name>, <name><surname>Ward</surname><given-names>E.</given-names></name>, <name><surname>Hao</surname><given-names>Y.</given-names></name></person-group>
<etal/> (<year>2008</year>) <article-title>Cancer statistics</article-title>. <source>CA Cancer J. Clin.</source>
<volume>58</volume>, <fpage>71</fpage>&#8211;<lpage>96</lpage>
<pub-id pub-id-type="doi">10.3322/CA.2007.0010</pub-id>
<?supplied-pmid 18287387?><pub-id pub-id-type="pmid">18287387</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>L.A.</given-names></name>, <name><surname>Bray</surname><given-names>F.</given-names></name>, <name><surname>Siegel</surname><given-names>R.L.</given-names></name>, <name><surname>Ferlay</surname><given-names>J.</given-names></name>, <name><surname>Lortet-tieulent</surname><given-names>J.</given-names></name> and <name><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>) <article-title>Global cancer statistics, 2012</article-title>. <source>CA Cancer J. Clin.</source>
<volume>65</volume>, <fpage>87</fpage>&#8211;<lpage>108</lpage>
<pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Center</surname><given-names>M.M.</given-names></name>, <name><surname>Jemal</surname><given-names>A.</given-names></name>, <name><surname>Smith</surname><given-names>R.A.</given-names></name> and <name><surname>Ward</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>) <article-title>Worldwide variations in colorectal cancer</article-title>. <source>Dis. Colon Rectum</source>
<volume>53</volume>, <fpage>1099</fpage></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betticher</surname><given-names>D.C.</given-names></name>, <name><surname>Thatcher</surname><given-names>N.</given-names></name>, <name><surname>Altermatt</surname><given-names>H.J.</given-names></name>, <name><surname>Hoban</surname><given-names>P.</given-names></name>, <name><surname>Ryder</surname><given-names>W.D.</given-names></name> and <name><surname>Heighway</surname><given-names>J.</given-names></name></person-group> (<year>1995</year>) <article-title>Alternate splicing produces a novel cyclin D1 transcript</article-title>. <source>Oncogene</source>
<volume>11</volume>, <fpage>1005</fpage>&#8211;<lpage>1011</lpage>
<?supplied-pmid 7675441?><pub-id pub-id-type="pmid">7675441</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>N.</given-names></name>, <name><surname>Hussain</surname><given-names>S.</given-names></name>, <name><surname>Kohaar</surname><given-names>I.</given-names></name>, <name><surname>Tabassum</surname><given-names>R.</given-names></name>, <name><surname>Nasare</surname><given-names>V.</given-names></name>, <name><surname>Tiwari</surname><given-names>P.</given-names></name></person-group>
<etal/> (<year>2009</year>) <article-title>Genetic variant of <italic>CCND1</italic>: association with HPV-mediated cervical cancer in Indian population</article-title>. <source>Biomarkers</source>
<volume>14</volume>, <fpage>219</fpage>&#8211;<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1080/13547500902825274</pub-id>
<?supplied-pmid 19489683?><pub-id pub-id-type="pmid">19489683</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>S.</given-names></name>, <name><surname>Sobti</surname><given-names>R.C.</given-names></name>, <name><surname>Kaur</surname><given-names>P.</given-names></name>, <name><surname>Gupta</surname><given-names>I.</given-names></name> and <name><surname>Jain</surname><given-names>V.</given-names></name></person-group> (<year>2008</year>) <article-title>Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population</article-title>. <source>Mol. Cell. Biochem.</source>
<volume>315</volume>, <fpage>151</fpage>&#8211;<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1007/s11010-008-9799-0</pub-id>
<?supplied-pmid 18548202?><pub-id pub-id-type="pmid">18548202</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasson</surname><given-names>M.K.</given-names></name>, <name><surname>Chauhan</surname><given-names>P.S.</given-names></name>, <name><surname>Singh</surname><given-names>L.C.</given-names></name>, <name><surname>Katara</surname><given-names>D.</given-names></name>, <name><surname>Sharma</surname><given-names>J.</given-names></name>, <name><surname>Zomawia</surname><given-names>E.</given-names></name></person-group>
<etal/> (<year>2014</year>) <article-title>Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis</article-title>. <source>Tumour Biol.</source>
<volume>35</volume>, <fpage>5885</fpage>&#8211;<lpage>5894</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-014-1779-2</pub-id>
<?supplied-pmid 24604328?><pub-id pub-id-type="pmid">24604328</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathyan</surname><given-names>K.M.</given-names></name>, <name><surname>Nalinakumari</surname><given-names>K.R.</given-names></name>, <name><surname>Abraham</surname><given-names>T.</given-names></name> and <name><surname>Kannan</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>) <article-title>Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility</article-title>. <source>Oral Oncol.</source>
<volume>42</volume>, <fpage>607</fpage>&#8211;<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1016/j.oraloncology.2005.10.019</pub-id>
<?supplied-pmid 16488657?><pub-id pub-id-type="pmid">16488657</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>M.</given-names></name>, <name><surname>Kumar</surname><given-names>S.</given-names></name>, <name><surname>Lal</surname><given-names>P.</given-names></name>, <name><surname>Tiwari</surname><given-names>A.</given-names></name>, <name><surname>Ghoshal</surname><given-names>U.C.</given-names></name> and <name><surname>Mittal</surname><given-names>B.</given-names></name></person-group> (<year>2007</year>) <article-title>Role of BCL2 (ala43thr), <italic>CCND1</italic> (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer</article-title>. <source>Cancer Detect. Prev.</source>
<volume>31</volume>, <fpage>225</fpage>&#8211;<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1016/j.cdp.2007.04.005</pub-id>
<?supplied-pmid 17561354?><pub-id pub-id-type="pmid">17561354</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>S.</given-names></name>, <name><surname>M</surname><given-names>Y.</given-names></name>, <name><surname>Thakur</surname><given-names>N.</given-names></name>, <name><surname>Salam</surname><given-names>I.</given-names></name>, <name><surname>Singh</surname><given-names>N.</given-names></name>, <name><surname>Mir</surname><given-names>M.M.</given-names></name></person-group>
<etal/> (<year>2011</year>) <article-title>Association of cyclin D1 gene polymorphisms with risk of esophageal squamous cell carcinoma in Kashmir Valley: a high risk area</article-title>. <source>Mol. Carcinog.</source>
<volume>50</volume>, <fpage>487</fpage>&#8211;<lpage>498</lpage>
<pub-id pub-id-type="doi">10.1002/mc.20732</pub-id>
<?supplied-pmid 21268129?><pub-id pub-id-type="pmid">21268129</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobti</surname><given-names>R.C.</given-names></name>, <name><surname>Kaur</surname><given-names>P.</given-names></name>, <name><surname>Kaur</surname><given-names>S.</given-names></name>, <name><surname>Singh</surname><given-names>J.</given-names></name>, <name><surname>Janmeja</surname><given-names>A.K.</given-names></name>, <name><surname>Jindal</surname><given-names>S.K.</given-names></name></person-group>
<etal/> (<year>2006</year>) <article-title>Effects of cyclin D1 (<italic>CCND1</italic>) polymorphism on susceptibility to lung cancer in a North Indian population</article-title>. <source>Cancer Genet. Cytogenet.</source>
<volume>15:170</volume>, <fpage>108</fpage>&#8211;<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.cancergencyto.2006.05.017</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangwar</surname><given-names>R.</given-names></name> and <name><surname>Mittal</surname><given-names>R.D.</given-names></name></person-group> (<year>2010</year>) <article-title>Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population</article-title>. <source>DNA Cell Biol.</source>
<volume>29</volume>, <fpage>349</fpage>&#8211;<lpage>356</lpage>
<pub-id pub-id-type="doi">10.1089/dna.2009.0982</pub-id>
<?supplied-pmid 20380574?><pub-id pub-id-type="pmid">20380574</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>R.K.</given-names></name> and <name><surname>Mittal</surname><given-names>R.D.</given-names></name></person-group> (<year>2010</year>) <article-title>Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?</article-title>
<source>Urol. Oncol.</source>
<volume>30</volume>, <fpage>555</fpage>&#8211;<lpage>561</lpage>
<pub-id pub-id-type="doi">10.1016/j.urolonc.2010.05.006</pub-id>
<?supplied-pmid 20822933?><pub-id pub-id-type="pmid">20822933</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govatati</surname><given-names>S.</given-names></name>, <name><surname>Singamsetty</surname><given-names>G.K.</given-names></name>, <name><surname>Nallabelli</surname><given-names>N.</given-names></name>, <name><surname>Malempati</surname><given-names>S.</given-names></name>, <name><surname>Rao</surname><given-names>P.S.</given-names></name>, <name><surname>Madamchetty</surname><given-names>V.K.</given-names></name></person-group>
<etal/> (<year>2014</year>) <article-title>Contribution of cyclin D1 (<italic>CCND1</italic>) and E-cadherin (CDH1) alterations to colorectal cancer susceptibility: a case-control study</article-title>. <source>Tumour Biol.</source>
<volume>35</volume>, <fpage>12059</fpage>&#8211;<lpage>12067</lpage>
<pub-id pub-id-type="doi">10.1007/s13277-014-2505-9</pub-id>
<?supplied-pmid 25146682?><pub-id pub-id-type="pmid">25146682</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sameer</surname><given-names>A.S.</given-names></name>, <name><surname>Parray</surname><given-names>F.Q.</given-names></name>, <name><surname>Dar</surname><given-names>M.A.</given-names></name>, <name><surname>Nissar</surname><given-names>S.</given-names></name>, <name><surname>Banday</surname><given-names>M.Z.</given-names></name>, <name><surname>Rasool</surname><given-names>S.</given-names></name></person-group>
<etal/> (<year>2013</year>) <article-title>Cyclin D1 G870A polymorphism and risk of colorectal cancer: a case control study</article-title>. <source>Mol. Med. Rep.</source>
<volume>7</volume>, <fpage>811</fpage>&#8211;<lpage>815</lpage>
<pub-id pub-id-type="doi">10.3892/mmr.2013.1287</pub-id>
<?supplied-pmid 23354584?><pub-id pub-id-type="pmid">23354584</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name>, <name><surname>Zheng</surname><given-names>R.</given-names></name>, <name><surname>Guo</surname><given-names>C.</given-names></name> and <name><surname>Niu</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>) <article-title>Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls</article-title>. <source>Diagn. Pathol.</source>
<volume>9</volume>, <fpage>168</fpage>
<pub-id pub-id-type="doi">10.1186/s13000-014-0168-x</pub-id><pub-id pub-id-type="pmid">25204741</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S.C.</given-names></name>, <name><surname>Zhong</surname><given-names>J.H.</given-names></name>, <name><surname>Tan</surname><given-names>J.T.</given-names></name>, <name><surname>Tang</surname><given-names>H.L.</given-names></name>, <name><surname>Liu</surname><given-names>X.G.</given-names></name>, <name><surname>Xiang</surname><given-names>B.D.</given-names></name></person-group>
<etal/> (<year>2015</year>) <article-title>Association between COX-2 gene polymorphisms and risk of hepatocellular carcinoma development: a meta-analysis</article-title>. <source>BMJ Open</source>, <volume>5</volume>
<pub-id pub-id-type="doi">10.1136/bmjopen-2015-008263</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>J.</given-names></name>, <name><surname>Wang</surname><given-names>M.</given-names></name>, <name><surname>Wang</surname><given-names>M.</given-names></name>, <name><surname>Fu</surname><given-names>S.</given-names></name>, <name><surname>Zhou</surname><given-names>D.</given-names></name>, <name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group>
<etal/> (<year>2011</year>) <article-title>
<italic>CCND1</italic> G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis</article-title>. <source>J. Cancer Res. Clin. Oncol.</source>
<volume>137</volume>, <fpage>489</fpage>&#8211;<lpage>494</lpage>
<pub-id pub-id-type="doi">10.1007/s00432-010-0904-x</pub-id>
<?supplied-pmid 20473525?><pub-id pub-id-type="pmid">20473525</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name>, <name><surname>Zeng</surname><given-names>X.</given-names></name>, <name><surname>Lu</surname><given-names>H.</given-names></name>, <name><surname>Ji</surname><given-names>H.</given-names></name>, <name><surname>Zhao</surname><given-names>E.</given-names></name> and <name><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>) <article-title>Association between cyclin D1 (<italic>CCND1</italic>) G870A polymorphism and gastric cancer risk: a meta-analysis</article-title>. <source>Oncotarget</source>
<volume>7</volume>, <fpage>66109</fpage>&#8211;<lpage>66118</lpage>
<?supplied-pmid 27623072?><pub-id pub-id-type="pmid">27623072</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.M.</given-names></name>, <name><surname>Ni</surname><given-names>X.B.</given-names></name>, <name><surname>Yang</surname><given-names>G.L.</given-names></name>, <name><surname>Luo</surname><given-names>Z.C.</given-names></name>, <name><surname>Niu</surname><given-names>Y.M.</given-names></name> and <name><surname>Shen</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>) <article-title>
<italic>CCND1</italic> G870A polymorphism and colorectal cancer risk: an updated meta-analysis</article-title>. <source>Mol. Clin. Oncol.</source>
<volume>4</volume>, <fpage>1078</fpage>&#8211;<lpage>1084</lpage>
<pub-id pub-id-type="doi">10.3892/mco.2016.844</pub-id>
<?supplied-pmid 27284448?><pub-id pub-id-type="pmid">27284448</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X.</given-names></name>, <name><surname>Zhang</surname><given-names>X.</given-names></name>, <name><surname>Wang</surname><given-names>B.</given-names></name>, <name><surname>Wang</surname><given-names>C.</given-names></name>, <name><surname>Jiang</surname><given-names>J.</given-names></name> and <name><surname>Wu</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>) <article-title>Association between polymorphism rs678653 in human cyclin D1 (<italic>CCND1</italic>) and susceptibility to cancer: a meta-analysis</article-title>. <source>Med. Sci. Monit.</source>
<volume>22</volume>, <fpage>863</fpage>&#8211;<lpage>874</lpage>
<pub-id pub-id-type="doi">10.12659/MSM.895237</pub-id>
<?supplied-pmid 26979757?><pub-id pub-id-type="pmid">26979757</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J.</given-names></name>, <name><surname>Liao</surname><given-names>X.</given-names></name>, <name><surname>Zhu</surname><given-names>J.</given-names></name>, <name><surname>Xue</surname><given-names>W.</given-names></name>, <name><surname>Shen</surname><given-names>G.</given-names></name>, <name><surname>Huang</surname><given-names>S.</given-names></name></person-group>
<etal/> (<year>2014</year>) <article-title>Association of <italic>MTHFR</italic> C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis</article-title>. <source>Sci. Rep.</source>, <pub-id pub-id-type="doi">10.1038/srep06159</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="book">(<year>2014</year>) <source>Review Manager (RevMan) [Computer program]. Version 5.3</source>, <publisher-name>The Nordic Cochrane Centre, The Cochrane Collaboration</publisher-name>, <publisher-loc>Copenhagen</publisher-loc></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantel</surname><given-names>N.</given-names></name> and <name><surname>Haenszel</surname><given-names>W.</given-names></name></person-group> (<year>1959</year>) <article-title>Statistical aspects of the analysis of data from retrospective studies of disease</article-title>. <source>J. Natl. Cancer Inst.</source>
<volume>22</volume>, <fpage>719</fpage>&#8211;<lpage>748</lpage>
<?supplied-pmid 13655060?><pub-id pub-id-type="pmid">13655060</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R.</given-names></name> and <name><surname>Laird</surname><given-names>N.</given-names></name></person-group> (<year>1986</year>) <article-title>Meta-analysis in clinical trials</article-title>. <source>Control. Clin. Trials</source>
<volume>7</volume>, <fpage>177</fpage>&#8211;<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id>
<?supplied-pmid 3802833?><pub-id pub-id-type="pmid">3802833</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>C.B.</given-names></name> and <name><surname>Mazumdar</surname><given-names>M.</given-names></name></person-group> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>
<volume>50</volume>, <fpage>1088</fpage>&#8211;<lpage>1101</lpage>
<pub-id pub-id-type="doi">10.2307/2533446</pub-id>
<?supplied-pmid 7786990?><pub-id pub-id-type="pmid">7786990</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M.</given-names></name>, <name><surname>Smith</surname><given-names>G.D.</given-names></name>, <name><surname>Schneider</surname><given-names>M.</given-names></name> and <name><surname>Minder</surname><given-names>C.</given-names></name></person-group> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>
<volume>315</volume>, <fpage>629</fpage>&#8211;<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id>
<?supplied-pmid 9310563?><pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brok</surname><given-names>J.</given-names></name>, <name><surname>Thorlund</surname><given-names>K.</given-names></name>, <name><surname>Gluud</surname><given-names>C.</given-names></name> and <name><surname>Wetterslev</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>) <article-title>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</article-title>. <source>J. Clin. Epidemiol.</source>
<volume>61</volume>, <fpage>763</fpage>&#8211;<lpage>769</lpage>
<pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.10.007</pub-id>
<?supplied-pmid 18411040?><pub-id pub-id-type="pmid">18411040</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>W.</given-names></name>, <name><surname>Zhuo</surname><given-names>Z.</given-names></name>, <name><surname>Chen</surname><given-names>Y.</given-names></name>, <name><surname>Zhu</surname><given-names>J.</given-names></name>, <name><surname>Zhao</surname><given-names>Z.</given-names></name>, <name><surname>Jia</surname><given-names>W.</given-names></name></person-group>
<etal/> (<year>2017</year>) <article-title>
<italic>NFKB1</italic> -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies</article-title>. <source>Oncotarget</source>
<volume>8</volume>, <fpage>9806</fpage>&#8211;<lpage>9822</lpage>
<?supplied-pmid 28039461?><pub-id pub-id-type="pmid">28039461</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Thorlund</surname><given-names>K.</given-names></name>, <name><surname>Engstr&#248;m</surname><given-names>J.</given-names></name>, <name><surname>Wetterslev</surname><given-names>J.</given-names></name>, <name><surname>Brok</surname><given-names>J.</given-names></name>, <name><surname>Imberger</surname><given-names>G.</given-names></name> and <name><surname>Gluud</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>) <source> User Manual for Trial Sequential Analysis (TSA)</source>, pp. <fpage>1</fpage>&#8211;<lpage>115</lpage>, <publisher-name> Copenhagen Trial Unit, Centre for Clinical Intervention Research</publisher-name>, <publisher-loc> Copenhagen, Denmark</publisher-loc>, <comment><ext-link ext-link-type="uri" xlink:href="http://www.ctu.dk/tsa">www.ctu.dk/tsa</ext-link></comment></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R.</given-names></name>, <name><surname>Chen</surname><given-names>C.</given-names></name>, <name><surname>Yu</surname><given-names>J.</given-names></name>, <name><surname>Huang</surname><given-names>X.</given-names></name>, <name><surname>Zhou</surname><given-names>M.</given-names></name> and <name><surname>Huang</surname><given-names>Z.</given-names></name></person-group> (<year>2014</year>) <article-title>Trial sequence meta-analysis can reject false-positive result calculated from conventional meta-analysis</article-title>. <source>Hepatology</source>
<volume>60</volume>, <fpage>1142</fpage>&#8211;<lpage>1143</lpage>
<pub-id pub-id-type="doi">10.1002/hep.27106</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catarino</surname><given-names>R.</given-names></name>, <name><surname>Matos</surname><given-names>A.</given-names></name>, <name><surname>Pinto</surname><given-names>D.</given-names></name>, <name><surname>Pereira</surname><given-names>D.</given-names></name>, <name><surname>Craveiro</surname><given-names>R.</given-names></name>, <name><surname>Vasconcelos</surname><given-names>A.</given-names></name></person-group>
<etal/> (<year>2005</year>) <article-title>Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism</article-title>. <source>Cancer Genet. Cytogenet.</source>
<volume>160</volume>, <fpage>49</fpage>&#8211;<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.cancergencyto.2004.11.017</pub-id>
<?supplied-pmid 15949570?><pub-id pub-id-type="pmid">15949570</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>H.</given-names></name>, <name><surname>Suzuki</surname><given-names>K.</given-names></name>, <name><surname>Satoh</surname><given-names>T.</given-names></name>, <name><surname>Ohtake</surname><given-names>N.</given-names></name>, <name><surname>Takei</surname><given-names>T.</given-names></name>, <name><surname>Nakata</surname><given-names>S.</given-names></name></person-group>
<etal/> (<year>2003</year>) <article-title>Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage</article-title>. <source>Anticancer Res.</source>
<volume>23</volume>, <fpage>4947</fpage>&#8211;<lpage>4951</lpage>
<?supplied-pmid 14981950?><pub-id pub-id-type="pmid">14981950</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>S.</given-names></name>, <name><surname>Amos</surname><given-names>C.I.</given-names></name>, <name><surname>Luthra</surname><given-names>R.</given-names></name>, <name><surname>Lynch</surname><given-names>P.M.</given-names></name>, <name><surname>Levin</surname><given-names>B.</given-names></name> and <name><surname>Frazer</surname><given-names>M.L.</given-names></name></person-group> (<year>2000</year>) <article-title>Effects of cyclin D1 polymorphism on age of hereditary nonpolyposis colorectal cancer</article-title>. <source>Cancer Res.</source>
<volume>60</volume>, <fpage>249</fpage>&#8211;<lpage>252</lpage>
<?supplied-pmid 10667569?><pub-id pub-id-type="pmid">10667569</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name>, <name><surname>Habuchi</surname><given-names>T.</given-names></name>, <name><surname>Takahashi</surname><given-names>T.</given-names></name>, <name><surname>Mitsumori</surname><given-names>K.</given-names></name>, <name><surname>Kamoto</surname><given-names>T.</given-names></name>, <name><surname>Kakehi</surname><given-names>Y.</given-names></name></person-group>
<etal/> (<year>2002</year>) <article-title>Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer</article-title>. <source>Carcinogenesis</source>
<volume>23</volume>, <fpage>257</fpage>&#8211;<lpage>264</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/23.2.257</pub-id>
<?supplied-pmid 11872630?><pub-id pub-id-type="pmid">11872630</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y.</given-names></name>, <name><surname>Shen</surname><given-names>H.</given-names></name>, <name><surname>Sturgis</surname><given-names>E.M.</given-names></name>, <name><surname>Wang</surname><given-names>L.E.</given-names></name>, <name><surname>Eicher</surname><given-names>S.A.</given-names></name>, <name><surname>Strom</surname><given-names>S.S.</given-names></name></person-group>
<etal/> (<year>2001</year>) <article-title>Cyclin D1 polymorphism and risk for Squamous cell carcinoma of the head and neck: a case-control study</article-title>. <source>Carcinogenesis</source>
<volume>22</volume>, <fpage>1195</fpage>&#8211;<lpage>1199</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/22.8.1195</pub-id>
<?supplied-pmid 11470749?><pub-id pub-id-type="pmid">11470749</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pabalan</surname><given-names>N.</given-names></name>, <name><surname>Bapat</surname><given-names>B.</given-names></name>, <name><surname>Sung</surname><given-names>L.</given-names></name>, <name><surname>Jarjanazi</surname><given-names>H.</given-names></name>, <name><surname>Pabalan</surname><given-names>O.F.</given-names></name> and <name><surname>Ozcelik</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>) <article-title>Cyclin D1 Pro241Pro (<italic>CC ND1</italic>-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis, cancer</article-title>. <source>Epidemiol. Biomarkers Prev.</source>
<volume>17</volume>, <fpage>2773</fpage>&#8211;<lpage>2781</lpage>
<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-08-0169</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>T.</given-names></name>, <name><surname>Chen</surname><given-names>J.</given-names></name>, <name><surname>Liu</surname><given-names>J.J.</given-names></name>, <name><surname>Li</surname><given-names>H.</given-names></name>, <name><surname>You</surname><given-names>X.M.</given-names></name>, <name><surname>Wang</surname><given-names>H.L.</given-names></name></person-group>
<etal/> (<year>2016</year>) <article-title>Association between cyclin D1 G870A polymorphism and hepatocellular carcinoma risk: a meta-analysis</article-title>. <source>Onco. Targets Ther.</source>
<volume>21</volume>, <fpage>4483</fpage>&#8211;<lpage>4489</lpage>
<pub-id pub-id-type="doi">10.2147/OTT.S108754</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M.</given-names></name>, <name><surname>Wan</surname><given-names>L.</given-names></name>, <name><surname>He</surname><given-names>X.</given-names></name>, <name><surname>Qi</surname><given-names>X.</given-names></name>, <name><surname>Liu</surname><given-names>F.</given-names></name> and <name><surname>Zhang</surname><given-names>D.H.</given-names></name></person-group> (<year>2015</year>) <article-title>Effect of the <italic>CCND1</italic> A870G polymorphism on prostate cancer risk: a meta-analysis of 3,820 cases and 3,825 controls</article-title>. <source>World J. Surg. Oncol.</source>
<volume>13</volume>, <fpage>55</fpage>
<pub-id pub-id-type="doi">10.1186/s12957-015-0479-8</pub-id>
<?supplied-pmid 25888980?><pub-id pub-id-type="pmid">25888980</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name>, <name><surname>Jiang</surname><given-names>L.</given-names></name> and <name><surname>Xu</surname><given-names>Q.</given-names></name></person-group>, <year>2018</year>
<article-title>A comprehensive evaluation for polymorphisms in let-7 family in cancer risk and prognosis: a system review and meta-analysis</article-title>. <source>Biosci. Rep.</source>, <volume>38</volume>, <fpage>BSR20180273</fpage>, <pub-id pub-id-type="doi">10.1042/BSR20180273</pub-id><pub-id pub-id-type="pmid">29717029</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L.Y.</given-names></name>, <name><surname>Zhao</surname><given-names>L.G.</given-names></name>, <name><surname>Chen</surname><given-names>X.</given-names></name>, <name><surname>Yang</surname><given-names>Z.</given-names></name> and <name><surname>Mo</surname><given-names>W.N.</given-names></name></person-group> (<year>2014</year>) <article-title>The <italic>CCND1</italic> G870A gene polymorphism and leukemia or non-Hodgkin lymphoma risk: a meta-analysis</article-title>. <source>Asian Pac. J. Cancer Prev.</source>
<volume>15</volume>, <fpage>6923</fpage>&#8211;<lpage>6928</lpage>
<pub-id pub-id-type="doi">10.7314/APJCP.2014.15.16.6923</pub-id>
<?supplied-pmid 25169547?><pub-id pub-id-type="pmid">25169547</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H.</given-names></name>, <name><surname>Fang</surname><given-names>L.</given-names></name> and <name><surname>Lin</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>) <article-title>Association of cyclin D1 variants with head and neck cancer susceptibility: evidence from a meta-analysis</article-title>. <source>Asian Pac. J. Cancer Prev.</source>
<volume>15</volume>, <fpage>5645</fpage>&#8211;<lpage>5651</lpage>
<pub-id pub-id-type="doi">10.7314/APJCP.2014.15.14.5645</pub-id>
<?supplied-pmid 25081680?><pub-id pub-id-type="pmid">25081680</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M.</given-names></name>, <name><surname>Zhu</surname><given-names>H.</given-names></name>, <name><surname>Hu</surname><given-names>T.</given-names></name>, <name><surname>Liu</surname><given-names>S.</given-names></name> and <name><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>) <article-title>Association of <italic>CCND1</italic> gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis</article-title>. <source>Int. J. Clin. Exp. Med.</source>
<volume>8</volume>, <fpage>12983</fpage>&#8211;<lpage>12988</lpage>
<?supplied-pmid 26550218?><pub-id pub-id-type="pmid">26550218</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sergentanis</surname><given-names>T.N.</given-names></name> and <name><surname>Economopoulos</surname><given-names>K.P.</given-names></name></person-group> (<year>2011</year>) <article-title>Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls</article-title>. <source>Mol. Biol. Rep.</source>
<volume>38</volume>, <fpage>4955</fpage>&#8211;<lpage>4963</lpage>
<pub-id pub-id-type="doi">10.1007/s11033-010-0639-4</pub-id>
<?supplied-pmid 21161398?><pub-id pub-id-type="pmid">21161398</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.</given-names></name>, <name><surname>Dong</surname><given-names>J.</given-names></name>, <name><surname>Ma</surname><given-names>H.</given-names></name>, <name><surname>Jin</surname><given-names>G.</given-names></name>, <name><surname>Hu</surname><given-names>Z.</given-names></name>, <name><surname>Peng</surname><given-names>Y.</given-names></name></person-group>
<etal/> (<year>2009</year>) <article-title>
<italic>CCND1</italic> G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis</article-title>. <source>Breast Cancer Res. Treat.</source>
<volume>116</volume>, <fpage>571</fpage>&#8211;<lpage>575</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-008-0195-y</pub-id>
<?supplied-pmid 18819000?><pub-id pub-id-type="pmid">18819000</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name>, <name><surname>Shen</surname><given-names>L.</given-names></name> and <name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2012</year>) <article-title>Specific <italic>CCND1</italic> G870A Alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls</article-title>. <source>Asian Pacific J. Cancer Prev.</source>
<volume>13</volume>, <fpage>5023</fpage>&#8211;<lpage>5025</lpage>
<pub-id pub-id-type="doi">10.7314/APJCP.2012.13.10.5023</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soleimani</surname><given-names>Z.</given-names></name>, <name><surname>Kheirkhah</surname><given-names>D.</given-names></name>, <name><surname>Sharif</surname><given-names>M.R.</given-names></name>, <name><surname>Sharif</surname><given-names>A.</given-names></name>, <name><surname>Karimian</surname><given-names>M.</given-names></name> and <name><surname>Aftabi</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>) <article-title>Association of <italic>CCND1</italic> gene c.870G&gt;A polymorphism with breast cancer risk: a case-control study and a meta-analysis</article-title>. <source>Pathol. Oncol. Res.</source>, <pub-id pub-id-type="doi">10.1007/s12253-016-0165-3</pub-id>
<?supplied-pmid 28004353?><pub-id pub-id-type="pmid">28004353</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>L.</given-names></name>, <name><surname>Hu</surname><given-names>Y.Y.</given-names></name>, <name><surname>Yang</surname><given-names>G.L.</given-names></name> and <name><surname>Liu</surname><given-names>D.X.</given-names></name></person-group> (<year>2014</year>) <article-title>
<italic>CCND1</italic> G870A polymorphism contributes to the risk of esophageal cancer: An updated systematic review and cumulative meta-analysis</article-title>. <source>Biomed. Rep.</source>
<volume>2</volume>, <fpage>549</fpage>&#8211;<lpage>554</lpage>
<pub-id pub-id-type="doi">10.3892/br.2014.286</pub-id><pub-id pub-id-type="pmid">24944806</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>W.</given-names></name>, <name><surname>Wang</surname><given-names>Z.T.</given-names></name>, <name><surname>Zhong</surname><given-names>J.</given-names></name> and <name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2013</year>) <article-title>Lack of association between Cyclin D1 gene G870A polymorphism and esophageal cancer: evidence from a meta-analysis</article-title>. <source>Genet. Mol. Res.</source>
<volume>12</volume>, <fpage>6636</fpage>&#8211;<lpage>6645</lpage>
<pub-id pub-id-type="doi">10.4238/2013.April.26.1</pub-id>
<?supplied-pmid 23661400?><pub-id pub-id-type="pmid">23661400</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W.</given-names></name>, <name><surname>Yu</surname><given-names>P.</given-names></name>, <name><surname>Wang</surname><given-names>Y.</given-names></name>, <name><surname>Kang</surname><given-names>M.</given-names></name>, <name><surname>Sun</surname><given-names>B.</given-names></name>, <name><surname>Yin</surname><given-names>J.</given-names></name></person-group>
<etal/> (<year>2015</year>) <article-title>Lack of association between cyclin D1 A870G (rs9344) polymorphism and esophageal squamous cell carcinoma risk: case-control study and meta-analysis</article-title>. <source>Int. J. Clin. Exp. Med.</source>
<volume>8</volume>, <fpage>12685</fpage>&#8211;<lpage>12695</lpage>
<?supplied-pmid 26550182?><pub-id pub-id-type="pmid">26550182</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J.</given-names></name>, <name><surname>Wang</surname><given-names>J.</given-names></name>, <name><surname>Suzuki</surname><given-names>S.</given-names></name>, <name><surname>Gajalakshmi</surname><given-names>V.</given-names></name>, <name><surname>Kuriki</surname><given-names>K.</given-names></name>, <name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group>
<etal/> (<year>2006</year>) <article-title>Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population</article-title>. <source>J. Cancer Res. Clin. Oncol.</source>
<volume>132</volume>, <fpage>193</fpage>&#8211;<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1007/s00432-005-0039-7</pub-id>
<?supplied-pmid 16328437?><pub-id pub-id-type="pmid">16328437</pub-id></mixed-citation></ref></ref-list></back></article>